UPB Stock Analysis: Buy, Sell, or Hold?
UPB - Upstream Bio, Inc. Common Stock
$7.25
0.38 (5.53%)
â˛
5d:
+14.9%
30d:
-7.17%
90d:
-19.31%
WAIT
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When UPB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: UPB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: UPB is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: UPB is currently trading at $7.25, which is considered slightly low relative to its 30-day fair value range of $6.49 to $7.47.
Technical Outlook: Technically, UPB is in a strong downtrend. The price is approaching resistance at $7.26. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: UPB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $38.25 (+427.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, UPB is in a strong downtrend. The price is approaching resistance at $7.26. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.5% recently.
Market Sentiment: UPB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $38.25 (+427.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$6.49 -
$7.47
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
100.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.5%)
- BULLISH: Trading 427.6% below Wall St target ($38.25)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.49 -
$7.47
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$6.09
Resistance Level
$7.26
Current Trend
Strong Downtrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.51
Wall Street Target
$38.25
(+427.6%)
Revenue Growth (YoY)
82.7%
Share & Embed Analysis
Last updated: August 08, 2026 5:25 AM ET
Data refreshes hourly during market hours. Next update: 6:25 AM
Data refreshes hourly during market hours. Next update: 6:25 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is UPB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Michael Gray
SELL
852 shares
2026-03-16
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 55 HOLD |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 52 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 56 HOLD |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 57 HOLD |
